Tb161-RAD402

N/A

Report date: 2026/03/13 20:02:36

Base Information

Drug NameTb161-RAD402

Drug Alias NameTb161-RAD402

ClassificationRadiation-emitting products > Nuclides > Terbium > 161TbRadiation-emitting products > Radionuclide Drug ConjugatesRadiation-emitting products > Radioactive therapeutic agent +[4]

Mechanisms of ActionAnti-PSA

TargetsProstate-specific antigen

Therapy Area/IndicationsProstatic Neoplasms, Castration-ResistantProstatic Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryAustralia

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaN/A

Originator CompaniesRadiopharm Theranostics Ltd

China Registration ClassN/A

Develop Information

Active CompaniesRadiopharm Theranostics Ltd

Inactive CompaniesN/A

Active IndicationsProstatic Neoplasms, Castration-ResistantProstatic Neoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A